日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications

肿瘤靶向肽-药物偶联物的创新设计理念：对新兴应用的洞察

期刊:Chinese Medical Journal
影响因子:7.3
doi:10.1097/CM9.0000000000003438
Tan, Ruirong; Yang, Zhenya; Xie, Jun; Wu, Zijun; Guo, Shanshan; Li, Li; Yin, Zhujun; Hua, Hua; Liu, Miao; Li, Rui
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Current landscape of innovative drug development and regulatory support in China

中国创新药物研发和监管支持的现状

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02267-y
Tan, Ruirong; Hua, Hua; Zhou, Siyuan; Yang, Zhimin; Yang, Changming; Huang, Guo; Zeng, Jin; Zhao, Junning
发表日期：2025
文献求助 收藏

SMYD3 Promotes Immune Evasion in Clear Cell Renal Cell Carcinoma via SREBP1-Mediated Transactivation of CD47.

SMYD3 通过 SREBP1 介导的 CD47 反式激活促进透明细胞肾细胞癌的免疫逃逸。

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202404200
Liu Zhengfang, Zhao Xiumei, Zang Maolin, Yuan Huiyang, Qin Xin, Li Xiaofeng, Zhao Shuo, Tan Ruirong, Yan Keqiang, Liu Li, Fan Yidong, Zhang Ning, Shi Benkang, Han Bo, Chen Shouzhen
细胞生物学
T细胞
CD4
EBP
CD47
EBP1
SMYD3
发表日期：2025
文献求助 收藏

Cryptotanshinone targets tumor-immune-microbiome axis to suppress colorectal cancer

隐丹参酮靶向肿瘤-免疫-微生物轴以抑制结直肠癌

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2025.1667500
Yang, Zhenya; Zhou, Mengting; Luo, Fenglin; Feng, Shiqi; Tan, Yu; Wang, Qiqian; Cheng, Zeneng; Tan, Ruirong; Li, Rui
肿瘤
肠癌
肿瘤免疫
微生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Overview of pharmacodynamical research of traditional Chinese medicine on hyperuricemic nephropathy: from the perspective of dual-regulatory effect on the intestines and kidneys

从肠肾双重调节作用的角度概述中药治疗高尿酸血症肾病的药效学研究

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2025.1517047
Wang, Ting; Li, Li; Liu, Li; Tan, Ruirong; Wu, Qinxuan; Zhu, Xin; Hua, Hua; Dai, Ying; Li, Huan; Mao, Jiuzhou; Zhao, Junning; Yin, Zhujun
发表日期：2025
文献求助 收藏

The cloacal outgrowth orchestrates co-development of the bladder and umbilical arteries

泄殖腔突起协调膀胱和脐动脉的共同发育

期刊:
影响因子:
doi:10.1101/2025.11.18.689093
Ye, Xing; Xia, Liguang; Yang, Xianfa; Tan, Ruirong; Zhang, Haochuan; Lei, Liming; Huang, Jungang; Zhang, Yingsheng; Morrisey, Edward; Zhu, Ping; Li, Zhongrong; Jing, Naihe; Li, Xue
发育与干细胞
发表日期：2025
文献求助 收藏

Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy

重新定义嵌合抗原受体T细胞（CAR-T）疗法的监管：中国应对CAR-T疗法继发性癌症风险的措施

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-024-01602-0
Tan, Ruirong; Li, Rui; Dai, Meng-Yuan; Liu, Miao; Zhao, Junning
肿瘤
T细胞
肿瘤免疫
信号转导
T细胞
细胞生物学
免疫/内分泌
发表日期：2024
文献求助 收藏

Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

利用细胞穿透肽诱导的嵌合体缀合物诱导DHHC3降解抑制PD-L1，从而治疗ICB耐药癌症

期刊:Cell Death & Disease
影响因子:9.6
doi:10.1038/s41419-024-07073-y
Shi, Yu-Ying; Fan, Gang; Tan, Ruirong; Li, Shan; Sun, Hua-Bing; Li, Rui; Yang, Mengni; Gao, Shanshan; Liu, Miao; Dai, Meng-Yuan
DHH
肿瘤
肿瘤免疫
PD-L1
细胞生物学
发表日期：2024
文献求助 收藏

Correction: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

更正：通过细胞穿透肽诱导的嵌合体缀合物诱导DHHC3降解来抑制PD-L1，从而治疗ICB耐药癌症

期刊:Cell Death & Disease
影响因子:9.6
doi:10.1038/s41419-024-07182-8
Shi, Yu-Ying; Fan, Gang; Tan, Ruirong; Li, Shan; Sun, Hua-Bing; Li, Rui; Yang, Mengni; Gao, Shanshan; Liu, Miao; Dai, Meng-Yuan
DHH
肿瘤
肿瘤免疫
PD-L1
细胞生物学
发表日期：2024
文献求助 收藏

Organoid modeling meets cancers of female reproductive tract

类器官模型应用于女性生殖道癌症

期刊:Cell Death Discovery
影响因子:7
doi:10.1038/s41420-024-02186-x
Li, Jiao; Zhou, Mengting; Xie, Jun; Chen, Jiani; Yang, Mengni; Ye, Changjun; Cheng, Shihu; Liu, Miao; Li, Rui; Tan, Ruirong
3D/类器官
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏